Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

The somatostatin analogue octreotide inhibits growth of small intestine neuroendocrine tumour cells.

Li SC, Martijn C, Cui T, Essaghir A, Luque RM, Demoulin JB, Castaño JP, Öberg K, Giandomenico V.

PLoS One. 2012;7(10):e48411. doi: 10.1371/journal.pone.0048411. Epub 2012 Oct 31.

2.

Effects of Somatostatin Analogs and Dopamine Agonists on Insulin-Like Growth Factor 2-Induced Insulin Receptor Isoform A Activation by Gastroenteropancreatic Neuroendocrine Tumor Cells.

van Adrichem RC, de Herder WW, Kamp K, Brugts MP, de Krijger RR, Sprij-Mooij DM, Lamberts SW, van Koetsveld PM, Janssen JA, Hofland LJ.

Neuroendocrinology. 2016;103(6):815-25. doi: 10.1159/000444280. Epub 2016 Feb 2.

3.

Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues.

Kaltsas GA, Papadogias D, Makras P, Grossman AB.

Endocr Relat Cancer. 2005 Dec;12(4):683-99. Review.

4.

Differential cytotoxicity of novel somatostatin and dopamine chimeric compounds on bronchopulmonary and small intestinal neuroendocrine tumor cell lines.

Kidd M, Drozdov I, Joseph R, Pfragner R, Culler M, Modlin I.

Cancer. 2008 Aug 15;113(4):690-700. doi: 10.1002/cncr.23700.

5.

Free somatostatin receptor fraction predicts the antiproliferative effect of octreotide in a neuroendocrine tumor model: implications for dose optimization.

Heidari P, Wehrenberg-Klee E, Habibollahi P, Yokell D, Kulke M, Mahmood U.

Cancer Res. 2013 Dec 1;73(23):6865-73. doi: 10.1158/0008-5472.CAN-13-1199. Epub 2013 Sep 30.

6.

Somatostatin receptor subtypes in neuroendocrine tumor cell lines and tumor tissues.

Jonas S, John M, Boese-Landgraf J, Häring R, Prevost G, Thomas F, Rosewicz S, Riecken EO, Wiedenmann B, Neuhaus P.

Langenbecks Arch Chir. 1995;380(2):90-5.

PMID:
7760656
7.

Inhibition of endothelial proliferation by the somatostatin analogue SOM230.

Adams RL, Adams IP, Lindow SW, Atkin SL.

Clin Endocrinol (Oxf). 2004 Oct;61(4):431-6.

PMID:
15473874
8.

Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures.

Mohamed A, Blanchard MP, Albertelli M, Barbieri F, Brue T, Niccoli P, Delpero JR, Monges G, Garcia S, Ferone D, Florio T, Enjalbert A, Moutardier V, Schonbrunn A, Gerard C, Barlier A, Saveanu A.

Endocr Relat Cancer. 2014 Oct;21(5):691-704. doi: 10.1530/ERC-14-0086. Epub 2014 Jul 10.

9.

Gene expression of somatostatin receptor 4 predicts clinical outcome of patients with metastatic neuroendocrine tumors treated with somatostatin analogs.

Slaby O, Sachlova M, Bednarikova M, Fabian P, Svoboda M, Vytopilova S, Valik D, Vyzula R.

Cancer Biother Radiopharm. 2010 Apr;25(2):237-43. doi: 10.1089/cbr.2009.0708.

PMID:
20423238
10.

Octreotide stimulates somatostatin receptor-induced apoptosis of SW480 colon cancer cells by activation of glycogen synthase kinase-3β, A Wnt/β-catenin pathway modulator.

Wang S, Bao Z, Liang QM, Long JW, Xiao ZS, Jiang ZJ, Liu B, Yang J, Long ZX.

Hepatogastroenterology. 2013 Oct;60(127):1639-46.

PMID:
24634935
11.

Neuroendocrine tumors in the brain.

Cavalla P, Schiffer D.

Ann Oncol. 2001;12 Suppl 2:S131-4.

PMID:
11762340
12.
13.

Cancer: antitumor effects of octreotide LAR, a somatostatin analog.

Oberg K.

Nat Rev Endocrinol. 2010 Apr;6(4):188-9. doi: 10.1038/nrendo.2010.3.

PMID:
20336162
14.

Expression of somatostatin receptors in human melanoma cell lines: effect of two different somatostatin analogues, octreotide and SOM230, on cell proliferation.

Martinez-Alonso M, Llecha N, Mayorga ME, Sorolla A, Dolcet X, Sanmartin V, Abal L, Casanova JM, Baradad M, Yeramian A, Egido R, Puig S, Vilella R, Matias-Guiu X, Marti RM.

J Int Med Res. 2009 Nov-Dec;37(6):1813-22.

PMID:
20146879
15.
16.

Somatostatin receptor subtypes in human non-functioning neuroendocrine tumors and effects of somatostatin analogue SOM230 on cell proliferation in cell line NCI-H727.

Ono K, Suzuki T, Miki Y, Taniyama Y, Nakamura Y, Noda Y, Watanabe M, Sasano H.

Anticancer Res. 2007 Jul-Aug;27(4B):2231-9.

17.

Chemotherapy and biotherapy in the treatment of neuroendocrine tumours.

Oberg K.

Ann Oncol. 2001;12 Suppl 2:S111-4. Review.

PMID:
11762335
18.

The octreotide suppression test and [111In-DTPA-D-Phe1]-octreotide scintigraphy in neuroendocrine tumours correlate with responsiveness to somatostatin analogue treatment.

Shi W, Buchanan KD, Johnston CF, Larkin C, Ong YL, Ferguson R, Laird J.

Clin Endocrinol (Oxf). 1998 Mar;48(3):303-9.

PMID:
9578820
19.

Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors.

Strosberg J, Kvols L.

World J Gastroenterol. 2010 Jun 28;16(24):2963-70.

20.

Somatostatin receptors: from signaling to clinical practice.

Theodoropoulou M, Stalla GK.

Front Neuroendocrinol. 2013 Aug;34(3):228-52. doi: 10.1016/j.yfrne.2013.07.005. Epub 2013 Jul 18. Review.

PMID:
23872332

Supplemental Content

Support Center